Abstract
Objective To assess whether the antiseizure medication levetiracetam may improve cognition in individuals with Alzheimer’s disease who have not previously experienced a seizure.
Methods We performed a randomised, double-blind, placebo-controlled crossover study in individuals with mild-to-moderate Alzheimer’s disease. Electroencephalography was performed at baseline and those with active epileptiform discharges were excluded. Eligible participants were randomised to placebo for 12 weeks or an active arm of oral levetiracetam (4 weeks up-titration to levetiracetam 500 mg twice daily, 4 weeks maintained on this dose followed by 4 weeks down-titration to nil). Participants then crossed over to the other arm. The primary outcome was change in cognitive function assessed by the Oxford Memory Task, a task sensitive to hippocampal memory binding. Secondary outcomes included tolerability, other neuropsychological scales and general questionnaires.
Results Recruitment numbers were severely limited owing to restrictions from the COVID-19 pandemic at the time of the study. Eight participants completed both arms of the study (mean age 68.4 years [SD=9.2]; 5 females [62.5%]).
No participants withdrew from the study and there was no significant difference between reported side-effects in the active levetiracetam or placebo arm. Measures of mood and quality of life were also not significantly different between the two arms based on participant or carer reports. In limited data analysis, there was no statistically significant difference between participants in the active levetiracetam and placebo arm on the memory task.
Significance This pilot study demonstrates that levetiracetam was well tolerated in individuals with Alzheimer’s disease, who do not have a history of seizures, and has no detrimental effect on mood or quality of life. Larger studies are needed to assess whether levetiracetam may have a positive effect on cognitive function in subsets of individuals with Alzheimer’s disease.
Plain language summary Abnormal electrical activity within the brain, such as is seen in seizures, might contribute to memory problems in people with dementia. We completed a clinical trial to see if the anti-seizure medication, levetiracetam, could help with memory difficulties in people with Alzheimer’s disease (the most common cause of dementia). In this pilot study, we could not prove whether levetiracetam helped memory function. We did show that the drug is safe and well-tolerated in people with dementia who have not had a seizure. This work therefore offers a platform for future research exploring anti-seizure medications in people with dementia.
Key points
Epilepsy may contribute to the aetiopathogenesis of Alzheimer’s disease
ILiAD is a double-blind, randomised placebo controlled trial of levetiracetam in Alzheimer’s disease
Levetiracetam was well tolerated in people with AD who have not had a seizure
Owing to small sample size, effect of levetiracetam on cognition could not be determined
Larger trials of anti-seizure medications in people with dementia are warranted
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03489044
Funding Statement
All data produced in the present study are available upon reasonable request to the authors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by Oxford Research Ethics Committee B and the Health Research Authority (National Health Service, England; ref no:17/SC/0468).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
